Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q7L014
UPID:
DDX46_HUMAN
Alternative names:
DEAD box protein 46; PRP5 homolog
Alternative UPACC:
Q7L014; O94894; Q96EI0; Q9Y658
Background:
The Probable ATP-dependent RNA helicase DDX46, also known as DEAD box protein 46 and PRP5 homolog, is pivotal in RNA splicing processes. Its role, either prior to or during the formation of the splicing A complex, underscores its importance in the post-transcriptional regulation of gene expression.
Therapeutic significance:
Understanding the role of Probable ATP-dependent RNA helicase DDX46 could open doors to potential therapeutic strategies.